Vanguard Global Advisers
IMDX icon

Vanguard Global Advisers’s Insight Molecular Diagnostics IMDX Stock Holding History

Vanguard Global Advisers’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$46.4K Buy
12,918
+7,143
+124% +$31.6K ﹤0.01% 3093
2026
Q2 		$34.1K Hold
5,775
– – ﹤0.01% 3192
2026
Q1 		$18.9K Buy
+5,775
New +$33.5K ﹤0.01% 3327

Other funds holding IMDX

AIC
AWM Investment Company New York $1.04B AUM 103.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Family Office Research
Family Office Research Bethesda, Maryland $260M AUM 20.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $109B AUM 29.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Global Advisers's IMDX Position: Q3 2026 in Review

Vanguard Global Advisers increased its Insight Molecular Diagnostics (IMDX) stake by 124% in Q3 2026, buying an estimated $31.6K and bringing the position to 12,918 shares worth $46.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3093.

Vanguard Global Advisers first reported a position in IMDX in Q1 2026 and has held it in 3 quarters since. 35 funds tracked by Wall St. Rank hold IMDX as of Q3 2026.

  • Vanguard Global Advisers held 12,918 shares of Insight Molecular Diagnostics worth $46.4K as of Q3 2026.
  • Vanguard Global Advisers bought 7,143 Insight Molecular Diagnostics shares in Q3 2026, an estimated $31.6K.
  • Insight Molecular Diagnostics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3093 holding.
  • Vanguard Global Advisers first reported a position in Insight Molecular Diagnostics in Q1 2026 and has held it in 3 quarters since.
  • 35 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.